Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice
2006

Review of NSAIDs, Coxibs, and Gastrointestinal Harm

Sample size: 34460 publication 10 minutes Evidence: high

Author Information

Author(s): R Andrew Moore, Sheena Derry, Ceri J Phillips, Henry J McQuay

Primary Institution: University of Oxford

Hypothesis

Do NSAIDs and coxibs differ in their gastrointestinal harm and effectiveness in clinical practice?

Conclusion

Coxibs show strong evidence of reduced gastrointestinal bleeding compared to NSAIDs, but many patients who need gastroprotection do not receive it.

Supporting Evidence

  • Evidence of efficacy of coxibs compared to NSAIDs for upper gastrointestinal bleeding was strong.
  • Patients receiving coxibs had more gastrointestinal risk factors than those receiving NSAIDs.
  • 76% of patients with at least one gastrointestinal risk factor received no prescription for gastroprotective agent with an NSAID.

Takeaway

Some pain medicines can hurt your stomach, but there are safer options. However, many people who need help don't get it.

Methodology

Systematic literature searches and analysis of clinical trials and observational studies.

Potential Biases

Channelling bias in observational studies due to differing risk factors among patients.

Limitations

Limited information on bowel damage and adherence to prescribed gastroprotection.

Participant Demographics

1.6 million patients studied, including 911,000 NSAID users.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2474-7-79

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication